Dron Jacqueline S, Hegele Robert A
Departments of Medicine and Biochemistry, and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A - 1151 Richmond Street North, London, ON N6A 5B7 Canada.
Curr Genet Med Rep. 2016;4(3):130-141. doi: 10.1007/s40142-016-0097-y. Epub 2016 Jun 7.
Plasma lipids, namely cholesterol and triglyceride, and lipoproteins, such as low-density lipoprotein (LDL) and high-density lipoprotein, serve numerous physiological roles. Perturbed levels of these traits underlie monogenic dyslipidemias, a diverse group of multisystem disorders. We are on the verge of having a relatively complete picture of the human dyslipidemias and their components.
Recent advances in genetics of plasma lipids and lipoproteins include the following: (1) expanding the range of genes causing monogenic dyslipidemias, particularly elevated LDL cholesterol; (2) appreciating the role of polygenic effects in such traits as familial hypercholesterolemia and combined hyperlipidemia; (3) accumulating a list of common variants that determine plasma lipids and lipoproteins; (4) applying exome sequencing to identify collections of rare variants determining plasma lipids and lipoproteins that via Mendelian randomization have also implicated gene products such as , , , , and as causal for atherosclerotic cardiovascular disease; and (5) using naturally occurring genetic variation to identify new drug targets, including inhibitors of apolipoprotein (apo) C-III, apo(a), ANGPTL3, and ANGPTL4.
Here, we compile this disparate range of data linking human genetic variation to plasma lipids and lipoproteins, providing a "one stop shop" for the interested reader.
血浆脂质,即胆固醇和甘油三酯,以及脂蛋白,如低密度脂蛋白(LDL)和高密度脂蛋白,发挥着多种生理作用。这些特征水平的紊乱是单基因血脂异常的基础,单基因血脂异常是一组多样的多系统疾病。我们即将对人类血脂异常及其组成部分有一个相对完整的认识。
血浆脂质和脂蛋白遗传学的最新进展包括以下几点:(1)扩大导致单基因血脂异常的基因范围,特别是低密度脂蛋白胆固醇升高;(2)认识到多基因效应在家族性高胆固醇血症和混合性高脂血症等特征中的作用;(3)积累一系列决定血浆脂质和脂蛋白的常见变异;(4)应用外显子组测序来识别决定血浆脂质和脂蛋白的罕见变异集合,通过孟德尔随机化,这些变异也表明诸如[此处原文可能缺失具体基因名称]等基因产物是动脉粥样硬化性心血管疾病的病因;(5)利用自然发生的基因变异来识别新的药物靶点,包括载脂蛋白(apo)C-III、apo(a)、血管生成素样蛋白3(ANGPTL3)和血管生成素样蛋白4(ANGPTL4)的抑制剂。
在此,我们汇总了将人类基因变异与血浆脂质和脂蛋白联系起来的这一系列不同的数据,为感兴趣的读者提供一个“一站式服务”。